利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.02 秒)

    Vehicle headlamp
    1.
    发明申请
    Vehicle headlamp 失效
    车头灯

    公开(公告)号：US20050117363A1

    公开(公告)日：2005-06-02

    申请号：US11001119

    申请日：2004-12-02

    申请人： Satoshi Yamamura ,  Hidetada Tanaka ,  Michio Tsukamoto ,  Noriko Okada

    发明人： Satoshi Yamamura ,  Hidetada Tanaka ,  Michio Tsukamoto ,  Noriko Okada

    IPC分类号： F21S8/10 ,  F21V7/00 ,  F21V11/16 ,  F21W101/10 ,  F21Y101/00 ,  B60Q1/04

    CPC分类号： F21S41/43 ,  F21S41/14 ,  F21S41/36 ,  F21S41/365

    摘要： A light source bulb is fixedly inserted into a lateral direction to the optical axis Ax at a position below an optical axis Ax. Accordingly, a region lateral to the optical axis Ax on a reflection surface of the reflector can be effectively utilized for light distribution control. Furthermore, a first additional reflector having a reflection surface of substantially-spheroidal shape whose first focal point is at a position coincident with the light source is disposed at a position above the optical axis Ax. A second additional reflector 36 having a reflection surface of a substantially-parabolic vertical cross-sectional profile whose focal point is coincident with a second focal point of the first additional reflector is disposed at a position below the optical axis. As a result, light from the light source is illuminated forward without passing through a projection lens.

    摘要翻译： 光源灯泡在光轴Ax下方的位置沿光轴Ax的横向方向固定地插入。 因此，可以有效地利用反射器的反射面上的光轴Ax侧面的区域进行配光控制。 此外，具有第一焦点位于与光源重合的位置的具有大致球状的反射面的第一附加反射体设置在光轴Ax上方的位置。 具有基本上抛物面的垂直横截面轮廓的反射表面的第二附加反射器36的焦点与第一附加反射体的第二焦点重合设置在光轴下方的位置。 结果，来自光源的光线向前照射而不通过投影透镜。

    Vehicle headlamp
    2.
    发明授权
    Vehicle headlamp 失效
    车头灯

    公开(公告)号：US07186009B2

    公开(公告)日：2007-03-06

    申请号：US11001119

    申请日：2004-12-02

    申请人： Satoshi Yamamura ,  Hidetada Tanaka ,  Michio Tsukamoto ,  Noriko Okada

    发明人： Satoshi Yamamura ,  Hidetada Tanaka ,  Michio Tsukamoto ,  Noriko Okada

    IPC分类号： F21V7/00

    CPC分类号： F21S41/43 ,  F21S41/14 ,  F21S41/36 ,  F21S41/365

    摘要： A light source bulb is fixedly inserted into a lateral direction to the optical axis Ax at a position below an optical axis Ax. Accordingly, a region lateral to the optical axis Ax on a reflection surface of the reflector can be effectively utilized for light distribution control. Furthermore, a first additional reflector having a reflection surface of substantially-spheroidal shape whose first focal point is at a position coincident with the light source is disposed at a position above the optical axis Ax. A second additional reflector 36 having a reflection surface of a substantially-parabolic vertical cross-sectional profile whose focal point is coincident with a second focal point of the first additional reflector is disposed at a position below the optical axis. As a result, light from the light source is illuminated forward without passing through a projection lens.

    摘要翻译： 光源灯泡在光轴Ax下方的位置沿光轴Ax的横向方向固定地插入。 因此，可以有效地利用反射器的反射面上的光轴Ax侧面的区域进行配光控制。 此外，具有第一焦点位于与光源重合的位置的具有大致球状的反射面的第一附加反射体设置在光轴Ax上方的位置。 具有基本上抛物面的垂直横截面轮廓的反射表面的第二附加反射器36的焦点与第一附加反射体的第二焦点重合设置在光轴下方的位置。 结果，来自光源的光线向前照射而不通过投影透镜。

    Methods and compositions for modulating C5-a-mediated inflammatory responses
    4.
    发明申请
    Methods and compositions for modulating C5-a-mediated inflammatory responses 有权
    调节C5-a介导的炎症反应的方法和组合物

    公开(公告)号：US20060063701A1

    公开(公告)日：2006-03-23

    申请号：US11202449

    申请日：2005-08-11

    申请人： Hidechika Okada ,  Noriko Okada

    发明人： Hidechika Okada ,  Noriko Okada

    IPC分类号： A61K38/10 ,  C07K7/08

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/472

    摘要： PL37 (RAARISLGPRICKAFTE [SEQ ID NO: 2]) is an Antisense Homolgoy Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow dissociation, whereas Pep-B failed to bind at all. C5a was inactivated by 7 nM or more of Pep-A and this concentration of Pep-A inhibited induction of intracellular Ca++ influx in neutrophils. Patch clamp studies also showed the effectiveness of Pep-A in C5a-receptor-expressing neuroblastoma cells. Pep-A administration prevented rats from C5a-mediated rapid lethal shock. A-Pep-A (Pep-A acetylated with alanine at the amino-terminus) was more stable in vivo and showed stronger inhibition of inflammatory reactions in mice and rats. Chemical modification of Pep-A (e.g., acetylation, or single or multiple amino acid replacement, insertion, or deletion within the native Pep-A sequence) will yield effective inhibitors, and will often improve inhibitory function on C5a anaphylatoxin. In such modified constructs it will often be desired to conserve some or all 5 prolines found in Pep-A to preserve inhibitory function on C5a.

    摘要翻译： PL37（RAARISL​​GPRICKAFTE [SEQ ID NO：2]）是由C5a-过敏毒素的氨基酸37至53组成的反义同源盒肽。 设计并表征互补肽ASGAPAPGPAGPLRPMF（Pep-A [SEQ ID NO：1]）和ASTAPARAGLPRLPKFF（Pep-B [SEQ ID NO：3]）。 Pep-A与PL37和C5a结合非常缓慢的解离，而Pep-B根本无法结合。 C5a被7nM或更多的Pep-A灭活，并且该浓度的Pep-A抑制嗜中性粒细胞内细胞内Ca ++流入的诱导。 补体钳研究还显示Pep-A在表达C5a受体的神经母细胞瘤细胞中的有效性。 Pep-A治疗阻止大鼠C5a介导的快速致死性休克。 A-Pep-A（在氨基末端用丙氨酸乙酰化的Pep-A）在体内更稳定，并且在小鼠和大鼠中表现出更强的炎症反应抑制。 Pep-A的化学修饰（例如，乙酰化，或天然Pep-A序列内的单个或多个氨基酸置换，插入或缺失）将产生有效的抑制剂，并且将经常改善对C5a过敏毒素的抑制功能。 在这种修饰的构建体中，通常需要保存Pep-A中发现的一些或全部5个脯氨酸以保持对C5a的抑制功能。

    Methods and compositions for modulating C5-a-mediated inflammatory responses
    5.
    发明授权
    Methods and compositions for modulating C5-a-mediated inflammatory responses 有权
    调节C5-a介导的炎症反应的方法和组合物

    公开(公告)号：US07763708B2

    公开(公告)日：2010-07-27

    申请号：US11202449

    申请日：2005-08-11

    申请人： Hidechika Okada ,  Noriko Okada

    发明人： Hidechika Okada ,  Noriko Okada

    IPC分类号： A61K38/10

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/472

    摘要： PL37 (RAARISLGPRCIKAFTE [SEQ ID NO: 2]) is an Antisense Homology Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow dissociation, whereas Pep-B failed to bind at all. C5a was inactivated by 7 nM or more of Pep-A and this concentration of Pep-A inhibited induction of intracellular Ca++ influx in neutrophils. Patch clamp studies also showed the effectiveness of Pep-A in C5a-receptor-expressing neuroblastoma cells. Pep-A administration prevented rats from C5a-mediated rapid lethal shock. A-Pep-A (Pep-A acetylated with alanine at the amino-terminus) was more stable in vivo and showed stronger inhibition of inflammatory reactions in mice and rats. Chemical modification of Pep-A (e.g., acetylation, or single or multiple amino acid replacement, insertion, or deletion within the native Pep-A sequence) will yield effective inhibitors, and will often improve inhibitory function on C5a anaphylatoxin. In such modified constructs it will often be desired to conserve some or all 5 prolines found in Pep-A to preserve inhibitory function on C5a.

    摘要翻译： PL37（RAARISL​​GPRCIKAFTE [SEQ ID NO：2]）是由C5a-过敏毒素的氨基酸37〜53构成的反义同源盒肽。 设计并表征互补肽ASGAPAPGPAGPLRPMF（Pep-A [SEQ ID NO：1]）和ASTAPARAGLPRLPKFF（Pep-B [SEQ ID NO：3]）。 Pep-A与PL37和C5a结合非常缓慢的解离，而Pep-B根本无法结合。 C5a被7nM或更多的Pep-A灭活，并且这种浓度的Pep-A抑制嗜中性粒细胞中细胞内Ca ++流入的诱导。 补体钳研究还显示Pep-A在表达C5a受体的神经母细胞瘤细胞中的有效性。 Pep-A治疗阻止大鼠C5a介导的快速致死性休克。 A-Pep-A（在氨基末端用丙氨酸乙酰化的Pep-A）在体内更稳定，并且在小鼠和大鼠中表现出更强的炎症反应抑制。 Pep-A的化学修饰（例如，乙酰化，或天然Pep-A序列内的单个或多个氨基酸置换，插入或缺失）将产生有效的抑制剂，并且将经常改善对C5a过敏毒素的抑制功能。 在这种修饰的构建体中，通常需要保存Pep-A中发现的一些或全部5个脯氨酸以保持对C5a的抑制功能。

    Lighting device for vehicle
    6.
    发明授权
    Lighting device for vehicle 失效
    车辆照明装置

    公开(公告)号：US07513654B2

    公开(公告)日：2009-04-07

    申请号：US11433598

    申请日：2006-05-12

    申请人： Noriko Okada

    发明人： Noriko Okada

    IPC分类号： F21V7/00

    CPC分类号： F21S41/37 ,  F21S41/143 ,  F21S41/147 ,  F21S41/285 ,  F21S41/321 ,  F21S41/322 ,  F21S41/36 ,  F21S41/365 ,  F21V7/06 ,  F21V7/08

    摘要： A lighting device for a vehicle has a light-emitting element disposed on an optical axis, a first reflection surface for reflecting light emitted from the light-emitting element in an outer radial direction of the optical axis, and a second reflection surface for reflecting the light reflected by the first reflection surface forward. A cross-sectional shape of the first reflection surface taken along a predetermined plane including the optical axis is an ellipse. The ellipse has a light-emitting center as a first focus and an axis line crossing the optical axis as a major axis. The second reflection surface is disposed between the first focus and a second focus of the ellipse. A cross-sectional shape of the second reflection surface taken along the predetermined plane is a parabola having the second focus of the ellipse as a focus and a point located forward of the focus as a vertex.

    摘要翻译： 车辆用照明装置具有配置在光轴上的发光元件，在光轴的外径方向上反射从发光元件射出的光的第一反射面和反射光的第二反射面 第一反射面向前反射的光。 沿着包括光轴的预定平面截取的第一反射表面的横截面形状是椭圆形。 椭圆具有作为第一焦点的发光中心和与光轴交叉的轴线作为长轴。 第二反射面设置在椭圆的第一焦点和第二焦点之间。 沿着预定平面截取的第二反射表面的横截面形状是具有作为焦点的椭圆的第二焦点和位于焦点的前方作为顶点的点的抛物线。

    Human igm antibody lysing activated lymphocytes under mediation by homologous complement
    7.
    发明申请
    Human igm antibody lysing activated lymphocytes under mediation by homologous complement 失效
    人类igm抗体通过同源补体在调解下溶解活化的淋巴细胞

    公开(公告)号：US20060140964A1

    公开(公告)日：2006-06-29

    申请号：US10520016

    申请日：2003-06-30

    申请人： Hidechika Okada ,  Noriko Okada

    发明人： Hidechika Okada ,  Noriko Okada

    IPC分类号： A61K39/42 ,  C07K16/10

    CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  Y10S530/809

    摘要： A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection

    摘要翻译： 获得了响应于HIV感染细胞的人IgM单克隆抗体，其特征在于通过同源人补体在介导下裂解活化的人淋巴细胞等。 使用如此获得的单克隆抗体，旨在提供含有人IgM单克隆抗体的免疫反应控制药物，其特异性响应于活化的淋巴细胞，并在同源补体的介导下诱导细胞裂解。 使用对活化的人淋巴细胞作出反应的人IgM单克隆抗体，还旨在提供HIV疗法等，其特征在于裂解和消除活化的淋巴细胞，从而治疗由T淋巴细胞过度反应引起的移植排斥反应和自身免疫性疾病 作为艾滋病毒感染

    Human IGM monoclonal antibody capable of inducing apoptosis in HIV-infected cells
    9.
    发明授权
    Human IGM monoclonal antibody capable of inducing apoptosis in HIV-infected cells 失效
    能够诱导HIV感染细胞凋亡的人IGM单克隆抗体

    公开(公告)号：US07595050B2

    公开(公告)日：2009-09-29

    申请号：US10519855

    申请日：2003-06-30

    申请人： Hidechika Okada ,  Noriko Okada

    发明人： Hidechika Okada ,  Noriko Okada

    IPC分类号： A61K39/42

    CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/73

    摘要： A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.

    摘要翻译： 属于特异性识别HIV感染细胞并诱导凋亡的人IgM类别的单克隆抗体。 使用获得的抗体旨在为患有HIV感染的患者提供补救措施，其包含作为活性成分的能够与HIV感染的细胞特异性反应的人IgM抗体，诱导感染的细胞中的细胞凋亡，从而破坏 细胞等

    Human igm antibody inducing apotosis in hiv-infected cells and remedy for hiv-infection
    10.
    发明申请
    Human igm antibody inducing apotosis in hiv-infected cells and remedy for hiv-infection 失效
    人igm抗体在HIV感染细胞中诱导凋亡，并用于HIV感染治疗

    公开(公告)号：US20060292160A1

    公开(公告)日：2006-12-28

    申请号：US10519855

    申请日：2003-06-30

    申请人： Hidechika Okada ,  Noriko Okada

    发明人： Hidechika Okada ,  Noriko Okada

    IPC分类号： A61K39/42 ,  C07K16/10

    CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/73

    摘要： A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.

    摘要翻译： 属于特异性识别HIV感染细胞并诱导凋亡的人IgM类别的单克隆抗体。 使用获得的抗体旨在为患有HIV感染的患者提供补救措施，其包含作为活性成分的能够与HIV感染的细胞特异性反应的人IgM抗体，诱导感染的细胞中的细胞凋亡，从而破坏 细胞等